Project Details
Description
CD16/IL-15/CD33 (161533) Tri specific Killer Engagers (TriKEs) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis
| Status | Active |
|---|---|
| Effective start/end date | 6/1/17 → 1/31/24 |
Funding
- GT BIOPHARMA, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.